In a nutshell The study evaluated the impact of granulocyte-colony stimulating factor (G-CSF; Neupogen) on the outcomes of brentuximab-vedotin (BV; Adcetris) plus chemotherapy in newly diagnosed patients with stage-III/IV Hodgkin lymphoma (HL). The authors found that G-CSF improved the safety and efficacy outcomes of the combination therapy in such...
Read More
In a nutshell This study looked at the lung function of patients with classical Hodgkin lymphoma (HL) in the first years of remission. It found that these survivors had higher rates of lung damage. Some background HL is a cancer of the lymph nodes which most often affects children and young adults. HL has good outcomes, and most patients with HL will...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of allogeneic stem cell transplantation (alloSCT) after immune checkpoint inhibitor (ICI) treatment in patients with classic Hodgkin lymphoma (cHL). This study concluded that this treatment is safe and has very good outcomes in these...
Read More
In a nutshell This study looked at the effect of pembrolizumab (Keytruda) to treat classical Hodgkin lymphoma (cHL) which had relapsed after previous treatments including brentuximab vedotin (Adcetris). It found that pembrolizumab was effective for these patients. Some background cHL is typically treated with chemotherapy, and sometimes with radiation...
Read More
In a nutshell This study looked at the targeted therapy nivolumab (Opdivo) to treat relapsed classical Hodgkin lymphoma (cHL). It found that most patients with relapsed cHL responded to nivolumab. Some background HL is a cancer of the lymph nodes which has good treatment options. However, roughly a third of patients with cHL will have the cancer...
Read More
In a nutshell This study aimed to investigate the long-term outcomes for patients with stage I-II classic Hodgkin lymphoma and unfavorable risk who were treated with Stanford V combined modality therapy. This study concluded that the long-term outcomes for these patients were favorable and comparable to other standard...
Read More
In a nutshell The study evaluated if brentuximab-vedotin (BV; Adcetris) consolidation therapy can reduce the use of radiation therapy (RT) in patients with limited-stage (LS) Hodgkin lymphoma (HL). The authors found that BV consolidation achieved good outcomes in such patients when given after ABVD therapy. Some background HL is a cancer of the...
Read More
In a nutshell This study compared the effectiveness of three low-intensity chemotherapy combinations to treat patients with classical Hodgkin lymphoma (HL) following stem cell transplantation (SCT). There were no significant differences between the three chemotherapy types in terms of patients’ survival and relapse. Some background...
Read More
In a nutshell This study examined the effectiveness and safety of immunotherapy before stem cell transplantation (SCT) in patients with Hodgkin lymphoma (HL). The authors concluded that this therapy increased the time before HL worsened and did not increase side effects. Some background Immunotherapy, including anti-PD-1 treatment such as...
Read More
In a nutshell This study looked at long-term outcomes of patients with early-stage Hodgkin lymphoma according to different treatments. It found that patients who received both radiation and chemotherapy had improved long-term survival compared to either treatment alone. Some background At present, over 90% of patients with classical Hodgkin lymphoma...
Read MoreIn a nutshell This study reviewed treatment options for older patients newly diagnosed with classical Hodgkin lymphoma (cHL). It found that treatments including brentuximab vedotin (BV: Adcetris) are effective in this age group and that avoiding bleomycin (Blenoxane) prevents lung damage. Some background Around 20% of patients diagnosed with cHL...
Read More
In a nutshell This review summarizes current treatment options of advanced classical Hodgkin lymphoma. It found that PET-scan based treatment minimizes long-term side effects and that both ABVD and eBEACOPP are useful chemotherapy regimens. Some background Classical Hodgkin lymphoma (cHL) is a cancer of white blood cells. If cancerous...
Read More
